🔎 Trials Near Me

Inicio › Sobrepeso › Arizona

Ensayos clínicos de Sobrepeso en Arizona

29 estudios sobre Sobrepeso buscan participantes en Arizona.

Ciudades en Arizona

Texto oficial del estudio (inglés)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

  • Headlands Research - Scottsdale /ID# 282571, Scottsdale
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 29 sept 2026 · NCT07752979

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

  • AMR Clinical, Tempe
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 28 sept 2026 · NCT07837973

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  • Care Access - 801 South Power Road, Mesa, Mesa
  • Absolute Clinical Research, Phoenix
  • Synexus Clinical Research US, Inc./Orange Grove Family Practice, Tucson
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07794579

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  • University of Arizona, Tucson
ReclutandoFase 3
Edades de 6 a 17 · Todos los sexos · Actualizado el 24 sept 2026 · NCT06672549

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler
  • Headlands Research - Scottsdale, Scottsdale
  • The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 22 sept 2026 · NCT07589608

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  • RIO Clinical Trials - Phoenix, Phoenix
  • Headlands Research - Scottsdale, Scottsdale
  • Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07392190

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  • Research Site, Mesa
  • Research Site, Phoenix
  • Research Site, Tucson
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07784270

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  • Care Access - 801 South Power Road, Mesa, Mesa
  • Elite Pain and Spine Institute - South Crimson Road, Mesa
  • Elite Clinical Studies, LLC, Phoenix
  • y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07353931

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  • Headlands Research - Scottsdale, Scottsdale
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07321886

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Synexus Clinical Research US, Inc., Phoenix
  • Medical Advancement Centers of Arizona, Phoenix
ReclutandoFase 3
Edades de 45 a 99 · Todos los sexos · Actualizado el 22 sept 2026 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  • Tucson Clinical Research Institute, Tucson
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07282600

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, Phoenix
  • AURORA-1 Clinical Site, Tucson
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Peoria
  • AURORA-2 Clinical Site, Phoenix
  • AURORA-2 Clinical Site, Tucson
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT07743450

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  • Arizona Clinical Trials, Tucson
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT07351058

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

  • Helios Clinical Research - Phoenix, Phoenix
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 14 sept 2026 · NCT06897475

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  • Arizona Clinical Trials, Tucson
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT07351045

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  • ACCOMPLISH-2 Research Site, Chandler
  • ACCOMPLISH-2 Research Site, Phoenix
  • ACCOMPLISH-2 Research Site, Sun City West
  • y 1 más
ReclutandoFase 3Se aceptan voluntarios sanos
Edades de 18 a 79 · Todos los sexos · Actualizado el 11 sept 2026 · NCT07654374

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

  • Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC, Gilbert
  • Synexus Clinical Research US, Inc., Phoenix
  • Pima Heart, Tucson
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 8 sept 2026 · NCT07215559

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler
  • Headlands Research - Scottsdale, Scottsdale
  • The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 8 sept 2026 · NCT06143956

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  • Kailera Clinical Site, Sun City
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT07284875

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

  • Gilbert Center for Family Medicine, Gilbert
ReclutandoFase 3
Edades de 18 a 99 · Todos los sexos · Actualizado el 3 sept 2026 · NCT07684144

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailera Clinical Site, Phoenix
  • Kailera Clinical Site, Sun City
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT07284901

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  • Arizona Clinical Trials, Chandler
  • Epic Medical Research - Sun City, Sun City
ReclutandoFase 3
Edades de 18 a 99 · Todos los sexos · Actualizado el 27 ago 2026 · NCT07575399

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  • Research Site, Mesa
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT07784725

Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity

  • Exponent Phoenix, Phoenix
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 ago 2026 · NCT07776678

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Phoenix
  • ACCOMPLISH-1 Research Site, Sun City West
  • ACCOMPLISH-1 Research Site, Tucson
ReclutandoFase 3
Edades de 18 a 79 · Todos los sexos · Actualizado el 10 ago 2026 · NCT07654361

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

  • The University of Arizona College of Medicine- Phoenix, Phoenix
ReclutandoFase 3
Edades de 18 a 75 · Todos los sexos · Actualizado el 14 nov 2025 · NCT06499857

De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.